Oral CHOP-like chemotherapy in 60-80 years-old patients with diffuse large B-cell lymphoma

Stephanie Guidez, Laurence Lacotte-Thierry, Cecile Tomowiak, Isabelle Princet, Brigitte Dreyfus, Gaelle Olivier, Emmanuel Fleck, Anne Corby, Carine Motard, Jocelyn Barrier, Antoine Machet, Katell Le Dû, Celine Debiais-Delpech, Michele Chabin, Xavier Leleu, Joëlle Guilhot, Vincent Delwail, Stephanie Guidez, Laurence Lacotte-Thierry, Cecile Tomowiak, Isabelle Princet, Brigitte Dreyfus, Gaelle Olivier, Emmanuel Fleck, Anne Corby, Carine Motard, Jocelyn Barrier, Antoine Machet, Katell Le Dû, Celine Debiais-Delpech, Michele Chabin, Xavier Leleu, Joëlle Guilhot, Vincent Delwail

No abstract available

Keywords: DLBCL; age 60-80 years; chemotherapy; idarubicin; oral treatment.

Conflict of interest statement

The authors declare no potential conflicts of interest

Figures

Figure 1
Figure 1
Survival curves. (A) Overall survival; (B) Event‐free survival; (C) Cumulative incidence of disease‐related events.

References

    1. Boogerd, W. , Tjahja, L.S. , van de Sandt, M.M. & Beijnen, J.H. (1999) Penetration of idarubicin into malignant brain tumor tissue. Journal of Neuro‐oncology, 44, 65–69.
    1. Cheson, B.D. , Horning, S.J. , Coiffier, B. , Shipp, M.A. , Fisher, R.I. , Connors, J.M. , Lister, T.A. , Vose, J. , Grillo‐López, A. , Hagenbeek, A. , Cabanillas, F. , Klippensten, D. , Hiddemann, W. , Castellino, R. , Harris, N.L. , Armitage, J.O. , Carter, W. , Hoppe, R. & Canellos, G.P. (1999) Report of an International Workshop to standardize response criteria for non‐Hodgkin’s lymphomas. Journal of Clinical Oncology, 17, 1244–1253.
    1. Coiffier, B. , Lepage, E. , Briere, J. , Herbrecht, R. , Tilly, H. , Bouabdallah, R. , Morel, P. , Van Den Neste, E. , Salles, G. , Gaulard, P. , Reyes, F. , Lederlin, P. & Gisselbrecht, C. (2002) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large B‐cell lymphoma. New England Journal of Medicine, 346, 235–242.
    1. Cunningham, D. , Hawkes, E.A. , Jack, A. , Qian, W. , Smith, P. , Mouncey, P. , Pocock, C. , Ardeshna, K.M. , Radford, J.A. , McMillan, A. , Davies, J. , Turner, D. , Kruger, A. , Johnson, P. , Gambell, J. & Linch, D. (2013) Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B‐cell non‐Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14‐day versus 21‐day cycles. Lancet, 381, 1817–1826.
    1. Delarue, R. , Tilly, H. , Mounier, N. , Petrella, T. , Salles, G. , Thieblemont, C. , Bologna, S. , Ghesquières, H. , Hacini, M. , Fruchart, C. , Ysebaert, L. , Fermé, C. , Casasnovas, O. , Van Hoof, A. , Thyss, A. , Delmer, A. , Fitoussi, O. , Molina, T.J. , Haioun, C. & Bosly, A. (2013) A. Dose‐dense rituximab‐CHOP compared with standard rituximab‐CHOP in elderly patients with diffuse large B‐cell lymphoma (the LNH03‐6B study): a randomised phase 3 trial. Lancet Oncology, 14, 525–533.
    1. Habermann, T.M. , Weller, E.A. , Morrison, V.A. , Gascoyne, R.D. , Cassileth, P.A. , Cohn, J.B. , Dakhil, S.R. , Woda, B. , Fisher, R.I. , Peterson, B.A. & Horning, S.J. (2006) Rituximab‐CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B‐cell lymphoma. Journal of Clinical Oncology, 24, 3121–3127.
    1. Hohloch, K. , Zwick, C. , Ziepert, M. , Hasenclever, D. , Kaiser, U. , Engert, A. , Höffkes, H.G. , Kroschinsky, F. , Mesters, R. , Feller, A.C. , Löffler, M. , Trümper, L. & Pfreundschuh, M. ; German High‐Grade Non‐Hodgkin´s Lymphoma Study Group (DSHNHL) . (2014) Significant dose escalation of idarubicin in the treatment of aggressive non‐Hodgkin lymphoma leads to increased hematotoxicity without improvement in efficacy in comparison to standard CHOEP‐ 14: 9‐year follow up results of the CIVEP trial of the DSHNHL. SpringerPlus, 3, 5–9.
    1. Kuffel, M.J. , Reid, J.M. & Ames, M.M. (1992) Anthracyclines and their C‐13 alcohol metabolites: growth inhibition and DNA damage following incubation with human tumor cells in culture. Cancer Chemotherapy and Pharmacology, 30, 51–57.
    1. Merli, F. , Luminari, S. , Rossi, G. , Mammi, C. , Marcheselli, L. , Tucci, A. , Ilariucci, F. , Chiappella, A. , Musso, M. , Di Rocco, A. , Stelitano, C. , Alvarez, I. , Baldini, L. , Mazza, P. , Salvi, F. , Arcari, A. , Fragasso, A. , Gobbi, P.G. , Liberati, A.M. & Federico, M. (2012) Cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab versus epirubicin, cyclophosphamide, vinblastine, prednisone and rituximab for the initial treatment of elderly “ fit ” patients with diff use large B‐cell lymphoma: results from the ANZINTER3 trial of the Intergruppo Italiano Linfomi. Leukemia & Lymphoma, 53, 581–588.
    1. Pfreundschuh, M. , Schubert, J. , Ziepert, M. , Schmits, R. , Mohren, M. , Lengfelder, E. , Reiser, M. , Nickenig, C. , Clemens, M. , Peter, N. , Bokemeyer, C. , Eimermacher, H. , Ho, A. , Hoffmann, M. , Mertelsmann, R. , Trümper, L. , Balleisen, L. , Liersch, R. , Metzner, B. , Hartmann, F. , Glass, B. , Poeschel, V. , Schmitz, N. , Ruebe, C. , Feller, A.C. & Loeffler, M. ; German High‐Grade Non‐Hodgkin Lymphoma Study Group (DSHNHL) . (2008) Six versus eight cycles of bi‐weekly CHOP‐14 with or without rituximab in elderly patients with aggressive CD20+ B‐cell lymphomas: a randomised controlled trial (RICOVER‐60). Lancet Oncology, 9, 105–116.

Source: PubMed

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

3
S'abonner